Israel, Iran And 2 Ways To Protect Your Money [View article]
Michael, Great article as always. I am also long PWE as well as ACTC (my favorite). Anyways, are you still confident with PWE and what future outlooks do have for this company? I am currently concerned with my investment in PWE and I'd like to hear your thoughts moving forward. Thank you
Silver Wheaton: This $30 Stock Is Easily Worth $40 [View article]
Great Article. My only question is why do you have no intention on starting a position in SLW when your future outlook is so positive. Please explain. I am long SLW
A Review Of My Last 3 Small Cap Bio-Pharma Picks [View article]
Thank you. I will also be following MELA closely as well. Both went up today with a great day as a whole for the market. Any other you would recommend for someone at my age? Thoughts on zlcs? Recommendations. I am also long ACTC as a large risk. Im hoping and expecting science to previal. GLTA
A Review Of My Last 3 Small Cap Bio-Pharma Picks [View article]
Scott, Great article. Considering taking a long position in AIS. 25 yr old beginning investor. What would be a good entry point for AIS? I'd like to get below $3. Is this realistic? Thx in advance and goodluck to all. Also, really enjoyed your info on MELA as well.
Speculative Biotech For The Iron-Stomached [View article]
After cohort 2, I'm sure MANY big pharmas will be either partnering with or putting up huge buyout offers for ACTC. 6 for 6 with efficacy and improvement with their injected patients. I'm sure we will be hearing more news shortly with both the SMD and AMD patients. No telling what a JV or buyout offer would do for ACTC's pps. Way way beyond where it currently sits.
ACTC is the most underrated stock out there. This stock could change all of medicine. Their pipeline is off the charts and has the ability to again, potentially change all of medicine. They are the current leader in regenerative medicine. Also, their patent protection is very solid and they hold the gold standard with their blastomere technology. Their is no limit to the upside of Advanced Cell Technology and this company is in the best financial situation they've been in throughout their companies history. So far they are 6 for 6 with 100% safety in efficacy in their phase 1 tests. Look for a pivotal phase to be in place after Cohort two within months. If this company signs a JV before the end of the yr. anything is possible. 1'000s % gains are possible IMO before the end of 2012. Also, this company may start seeing revenue as early as 2013 with SMD.
10 Biotech Stocks With Big Potential Upside In 2012: Part One [View article]
What is it that is so great about sppi??? Please help, I am considering a long position. Want more info and will do my DD. How can someone convince me? Lets hear it
2 Biotechs Hopefully To Get Rich Or Die Trying [View article]
You got that right MSF investment. Large volume and 20% boost the last two days combined on no news. Lets get that China JV signed and get the PR announced. Also, it is very important to investors to vote yes for the proxy. Reader, I hope you realize the importance of this vote to get through the lawsuit process. Voting no will simply delay everything and keep the lawsuits from being settled. You need to look at the bigger picture. Once ACTC can get thru these settlements, announce a JV partner, and announce the PR from the first two patients. We may be well on our way to $10.00. People will soon wake up to this opportunity. Lets get the ball rolling.
Investors And Traders In The Biotech Landscape [View article]
When are you expecting results from the first injected patients at Jules Stein for ACTC? Can we please expect the results and a possible JV within the next month?? I hope ACTC can deliver and not just be another dream stock that can't make it thru. It just seems as though the science seems so great. Good luck to us Michael
Why Perifosine Phase 3 Trials Will Likely Fail [View article]
What a sad article. Using a past article that is not legitimate based on market cap only to try to knock down the stock prices. Why aren't you short AEZS and KERX Adam???? With this type of writing and "your opinion" show us how strong "your opinion" really is. Why don't you short these now if your so strong based on a small market cap will fail their study results..... just because they are a small marker. Laughable.
Good article Mike. It appears that ACTC has made significant progress in the last couple weeks. I am long ACTC and am hoping to hear an announcement for a JV partnership within the next couple months. I am also anxiously waiting and hoping to hear phenomenal results from the first two injected patients and the announcement of another site ready to begin injections to provide more complete study results from multiple sites. If ACTC can announce positive results and announce a JV partnership, where can ACTC pps get to? I would also imagine they might announce these two positives along with a possible A/S announcement all at once. Just an opinion. Your thoughts??
Thanks again Mike. Goodluck!! Are you more confident with kerx and aezs with Perifosine or more confident with the science behind ACTC and a chance of a partnership?? Ha. Goodluck with both huh? Your opinion
Israel, Iran And 2 Ways To Protect Your Money [View article]
Great article as always. I am also long PWE as well as ACTC (my favorite). Anyways, are you still confident with PWE and what future outlooks do have for this company? I am currently concerned with my investment in PWE and I'd like to hear your thoughts moving forward. Thank you
Why Zalicus Looks Ready For A Bullish Move [View article]
Silver Wheaton: This $30 Stock Is Easily Worth $40 [View article]
A Review Of My Last 3 Small Cap Bio-Pharma Picks [View article]
A Review Of My Last 3 Small Cap Bio-Pharma Picks [View article]
7 Bullish Reasons To Buy Zalicus Right Now [View article]
Zalicus May Be 2012's 'Come Back Kid' Biotech Stock [View article]
Speculative Biotech For The Iron-Stomached [View article]
Weekly Stock Watch: Feb 27-March 2 [View article]
10 Biotech Stocks With Big Potential Upside In 2012: Part One [View article]
2 Biotechs Hopefully To Get Rich Or Die Trying [View article]
Investors And Traders In The Biotech Landscape [View article]
Why Perifosine Phase 3 Trials Will Likely Fail [View article]
Something Wicked This Way Comes [View article]
Biotechs And Their Trials By Fire [View article]